Newsletter Tool

PM Tracker

Today’s Big News

Jun 23, 2025

FDA's acting CDER head Corrigan-Curay heads for the exit amid period of heavy turnover: reports

Hims & Hers stock plunges 30% as Novo Nordisk terminates Wegovy direct sales deal

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

Lilly eyes global approval filings as once-weekly insulin candidate takes clinical victory lap

Diabetes and obesity boom will propel Lilly, Novo to front of pharma sales pack by 2030: Evaluate

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication

Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed

Illumina picks up proteomics developer SomaLogic from Standard BioTools for $425M

Featured

FDA's acting CDER head Jacqueline Corrigan-Curay heads for the exit amid period of heavy turnover: reports

By Eric Sagonowsky

Only a few days after reports emerged that the director of the FDA's cell and gene therapy office had been abruptly put on administrative leave, a new departure shows that an intense period of leadership turnover at the agency isn't over.

Hims & Hers stock plunges 30% as Novo Nordisk terminates Wegovy direct sales deal

By Heather Landi

Hims & Hers stock plunged around 30% on Monday after drugmaker Novo Nordisk abruptly ended a month-long collaboration to make its weight loss drug Wegovy available on the telehealth company's platform.

BrightGene tops Novo drug in diabetes ahead of Zepbound showdown

By Nick Paul Taylor

BrightGene Pharmaceutical has scored an early win in its push to topple the big beasts of the GLP-1 field. The biotech linked its challenger to bigger reductions in blood sugar than Novo Nordisk’s semaglutide, giving momentum as it barrels toward a readout from a head-to-head trial against Eli Lilly’s tirzepatide.

Lilly eyes global approval filings as once-weekly insulin candidate takes clinical victory lap

By Fraiser Kansteiner

Lilly provided a comprehensive look at positive results from a group of studies that assessed the company's once-a-week insulin candidate efsitora in multiple Type 2 diabetes patient populations. Lilly says it plans to submit its efsitora package to global regulators by the end of the year.

Diabetes and obesity boom will propel Lilly, Novo to front of pharma sales pack by 2030: Evaluate

By Kevin Dunleavy

Fueled by sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin, according to data analytics specialist Evaluate Pharma in its 2030 projection.

Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor in new indication

By James Waldron

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up to 545 million euros ($626 million) from a licensing deal with Sanofi.

Compass points to psychedelic therapy's phase 3 depression win, but investors unimpressed

By James Waldron

Compass Pathways' delayed phase 3 readout for its psilocybin treatment has hit its primary endpoint of reducing the severity of patients’ depression, but investors appear unimpressed.

Illumina picks up proteomics developer SomaLogic from Standard BioTools for $425M

By Conor Hale

Illumina is diving deeper into proteomics research with a $425 million plan to acquire SomaLogic, including its protein analysis platforms and certified lab services business.

AstraZeneca faces new allegations over trial data for blood thinner Brilinta: BMJ

By Kevin Dunleavy

Fourteen years after AstraZeneca’s blood thinner Brilinta reached the market and now faces generic competition, the data that backed its original approvals around the world has been called into question.